July #114 : New Kaletra, Nice to Meet Ya

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Southern Discomfort

Hot Type!

The Rath of Con

Earthwatch

On the March!

Milestones

AIDS Walk of Life

OOPS, They Did It Again

Read It and Weep

Legal Eye

Everyone's a Critic

POZ Picks

Brad Pity

Aren't You Due for a Vacation?

Before Packing

Planning by Numbers

Cleared for Takeoff

Staying Healthy on Holiday

Itinerary

Welcome Home

The Scoop on Ice Cream

You Gotta Move It

Zip 'Em Up

2 Is The Loneliest Number

C Note

New Kaletra, Nice to Meet Ya

Zerit Dosing

Take it From the Experts

Forbidden Fruit

Altared State

Shopping With Alice

Inside Job

Publisher's Letter



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

July 2005

New Kaletra, Nice to Meet Ya

In early May, the FDA approved once-daily dosing of Abbott’s powerhouse protease inhibitor (PI) Kaletra (lopinavir plus booster ritonavir)—but only for folks new to HIV meds. For now, the rest of you are stuck with the twice-a-day: Once-daily hasn’t been tested in old-timers, and some HIV docs and treatment advocates worry that the PI’s blood levels will fall too low over 24 hours to work in folks with resistant virus. And once-daily dosing comes with a caution as big and bold as Kaletra’s famously bright-orange capsule: The incidence of diarrhea may rise if you take Kaletra all at once rather than in two daily doses. Still, one dose is one less to worry about. And Abbott is reformulating the soft-gel capsule into a tablet, hoping that the new tab will table Kaletra’s gastro side effects. The tablet will reduce the daily pill total from six to four and may avoid the PI’s take-with-food restriction (it’s being tested with and without). What’s more, it will omit one ingredient—fatty oleic acid—which Abbott’s George Hanna, MD, fingers for the diarrhea and nausea. The new tabs are being tested in HIVers new and old to meds. Last but not least, Abbott foresees a Norvir (ritonavir) remix, so HIVers who use Norvir to boost other PIs may be able to kick those icky side effects, too.



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    soy_Ric
    Rochester
    New York


    pevans
    San Francisco
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.